Another study showing the dangers and ineffectiveness of chemotherapy has just been published and it has gone viral. The study titled Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism was published in the journal Science Translational Medicine describing how chemotherapy could allow cancer to spread, and trigger more aggressive tumors. By studying the process of intravasation, or entry of cells into the vasculature, the study’s authors discovered that chemotherapy, in addition to targeting tumor cells, can also increase intravasation. The authors found that chemotherapy increased groups of cells known as tumor microenvironment of metastasis (TMEM) which collectively usher tumor cells into the body’s vasculature. The study discovered that several types of chemotherapy can increase the amounts of TMEM complexes and circulating tumor cells in the bloodstream. Why is this important? The chances of survival dramatically decrease once cancer begins to metastasize through the bloodstream and effect other organs and systems.
Is the recent study the only one painting chemotherapy as a dangerous treatment option? In 2016 a groundbreaking study was commissioned by Public Health England and published in the journal Lancet Oncology. The study represented the first time that national data has been gathered together and analyzed for 30-day mortality after chemotherapy. It found that a larger proportion of patients are actually dying after chemotherapy than in the clinical trials carried out by the drug companies. The death rate in the clinical trials of drug treatments for lung cancer was 0.8%, but in the present study the reality shows it is actually 3%.
What happens when the extended survival rate of chemotherapy as a cancer treatment is studied beyond 30 days? An Australian study published in the journal Clinical Oncology found the contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies in adults was estimated to be 2.3% in Australia and 2.1% in the US. In fact, the study concluded by stating:
“To justify the continued funding and availability of drugs used in cytotoxic chemotherapy, a rigorous evaluation of the cost-effectiveness and impact on quality of life is urgently required.”